Market Access News | pharmaphorum

News

GB first to approve Roche's subcutaneous Tecentriq

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

One year on, ABPI asks why IMF hasn't funded any drugs

The Innovative Medicines Fund (IMF), set up in the UK last year to fast-track NHS access to promising new drugs, still hasn't provided any funding for a new medicine, and

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News

Changing Faces: Pharma supplier hires from July 2023

In our second hires round-up for the month of July, we look at hires in pharma-adjacent industries like CROs, CDMOs, med device, and digital health.

News

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower r

GB first to approve Roche's subcutaneous Tecentriq

BMS grabs key approval for Reblozyl in MDS

One year on, ABPI asks why IMF hasn't funded any drugs

First Tysabri biosimilar cleared by FDA for MS

Changing Faces: Pharma supplier hires from July 2023

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks